The number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk https://www.reuters.com/markets/companies/NOVOb.CO” target=”_blank” rel=”noopener”>(NOVOb.CO) that belongs to a class of GLP-1 drugs, could nearly double next year, a…
Read More
About The Author
